Correction to: Leukemia https://doi.org/10.1038/s41375-021-01157-w, published online 15 February 2021

Following the publication of this article, the authors noted an error in the data reported.

One patient in the AML-D11 study (showing negativity for both FCM-MRD and GATA1-MRD) was incorrectly reported dead after relapse following a data input error. After re-confirming the survival data for all other patients, the dataset has been updated and results are as follows.

  • The number of patients who relapsed was decreased from 7 to 6.

  • The 3-year event-free survival (EFS) and overall survival (OS) rates in the entire population (n = 78) were 88.5 and 91.0%.

  • The 3-year EFS and OS rates in the SR patients (n = 76) were 90.8 and 93.4%.

  • The 3-year EFS and OS rates were 95.0 and 96.7% in the FCM-MRD-negative population, and 60.0 and 80.0% in the positive population.

  • Three-year EFS and OS rates were both 98.1% in the GATA1-MRD-negative population, and 57.1 and 71.4% in the positive population.

  • The adjusted hazard ratios for the association of FCM-MRD with EFS and OS were 14.67 (95% CI, 2.00–107.79; p = 0.01) and 13.48 (0.81–224.27; p = 0.07), respectively, while multivariate analysis of GATA1-MRD did not converge in the updated dataset due to the limited number of events in the GATA1-MRD-negative population.

Table 2, Supplementary Table 4, and Figs. 3 and 4 have been corrected and are shown below.

The conclusions of the article remain unchanged.

Table 2 Multivariate Cox regression of FCM-MRD for event-free and overall survivals in the standard risk population.
Full size table